Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Global R&D, CSO | June 16, 2014 | June 18, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 16, 2014 · Filed June 18, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,017 |
Reported balance
After 2014-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017 |
| Common StockSEC Table I · non-derivative | Direct | 146,614 |
Reported balance
After 2014-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 145,114 |
Reported balance
After 2014-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). |
| Common StockSEC Table I · non-derivative | Direct | 143,517 |
Reported balance
After 2014-06-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). |
| Common StockSEC Table I · non-derivative | Direct | 144,517 |
Reported balance
After 2014-06-16 transaction · row 4
1 source rowRow 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23 | Direct | 15,500 |
Reported balance
After 2014-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,770 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,770 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 5,568 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,568 |
| Common StockSEC Table I · non-derivative | IndirectCommon stock held in trust | 15,233 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
F7: Common stock held in grantor retained annuity trust.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2010 Filed Apr 16, 2010 19:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $39.61 | $63,376.00 |
DisclosureSEC source: 0000875320-10-000018 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.61 (range $39.42 to $39.87). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 19:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000018 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $43.08 | $68,928.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $43.08 (range $42.80 to $43.52). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000016 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $38.55 | $61,680.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $38.55 (range $38.46 to $38.65). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 18:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000014 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 108,750 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000007 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 108,750 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0000875320-10-000007 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,505 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| February 03, 2010 Filed Feb 4, 2010 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,844 | $40.07 | $154,029.08 |
DisclosureSEC source: 0000875320-10-000004 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,004 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan establishded under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.07 (range $40.02 to $40.23). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2010 Filed Jan 27, 2010 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,026 | $39.39 | $79,804.14 |
DisclosureSEC source: 0000875320-10-000002 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,848 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan establishded under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.39 (range $39.15 to $39.62). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2010 Filed Jan 19, 2010 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-10-000001 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 15, 2010 Filed Jan 19, 2010 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $41.34 | $12,402.00 |
DisclosureSEC source: 0000875320-10-000001 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,874 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $41.34 (range $40.94 to $41.74). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2010 Filed Jan 19, 2010 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $40.09 | $52,117.00 |
DisclosureSEC source: 0000875320-10-000001 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,174 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.09 (range $39.83 to $40.37). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2010 Filed Jan 19, 2010 18:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-10-000001 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2009 Filed Dec 9, 2009 15:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-09-000101 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 04, 2009 Filed Dec 9, 2009 15:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $39.62 | $63,392.00 |
DisclosureSEC source: 0000875320-09-000101 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,874 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.62 (range $39.29 to $40.24). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2009 Filed Dec 9, 2009 15:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,600 | $10.41 | $16,656.00 |
DisclosureSEC source: 0000875320-09-000101 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2009 Filed Oct 26, 2009 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 300,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0000875320-09-000091 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2019-10-21 F1 · derivative.exercise_date: Stock option under 2006 Stock and Option Plan, vesting on 10/22/2014, subject to 20% acceleration upon receiving U.S. marketing approval for telaprevir; up to an additional 40% acceleration upon receiving U.S. approval for telaprevir if certain other performance goals are achieved; and 40% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of an additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| July 16, 2009 Filed Jul 20, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0000875320-09-000062 · edgar.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2019-07-15 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09. Read SEC document |
| July 15, 2009 Filed Jul 17, 2009 13:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000060 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| July 15, 2009 Filed Jul 17, 2009 13:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $32.88 | $78,912.00 |
DisclosureSEC source: 0000875320-09-000060 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,874 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.88 (range $32.50 to $33.09). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2009 Filed Jul 17, 2009 13:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000060 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000046 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $31.02 | $74,448.00 |
DisclosureSEC source: 0000875320-09-000046 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,874 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $31.02 (range $30.79 to $31.40). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 17:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000046 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2009 Filed May 19, 2009 18:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000032 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 15, 2009 Filed May 19, 2009 18:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $28.56 | $68,544.00 |
DisclosureSEC source: 0000875320-09-000032 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,874 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.56 (range $28.42 to $28.73). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2009 Filed May 19, 2009 18:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000032 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2009 Filed May 11, 2009 18:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,796 | $28.94 | $370,316.24 |
DisclosureSEC source: 0000875320-09-000024 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,796 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan establishded under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.94 (range $28.71 to $29.20). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 17:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000019 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 17:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $26.98 | $64,752.00 |
DisclosureSEC source: 0000875320-09-000019 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,670 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $26.98 (range $26.64 to $27.19). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 17:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000019 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $28.98 | $28,980.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,356 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $28.98 (range $28.76 to $29.13). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,400 | $28.05 | $39,270.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,356 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.05 (range $27.60 to $28.50). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 16, 2009 Filed Mar 17, 2009 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000017 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,400 shares Expires 2014-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $32.88 | $78,912.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,356 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $32.88 (range $32.55 to $33.14). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.69 | $23,256.00 |
DisclosureSEC source: 0000875320-09-000016 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 54,375 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2019-02-04 F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,356 F5 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 218 | $34.07 | $7,427.26 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,272 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $34.07 (range $34.02 to $34.13). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2009 Filed Feb 6, 2009 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $33.55 | $30,195.00 |
DisclosureSEC source: 0000875320-09-000006 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,490 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $33.55 (range $32.96 to $33.94). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $29.63 | $71,112.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.63 (range $29.19 to $30.05). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2009 Filed Jan 16, 2009 17:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,400 | $9.07 | $21,768.00 |
DisclosureSEC source: 0000875320-09-000001 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 18:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 2,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-08-000096 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 18:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $25.81 | $61,944.00 |
DisclosureSEC source: 0000875320-08-000096 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP Drug Innov.& Realiz, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,390 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.